MR Metformin and SGLT2i Now First-Line in Type 2 Diabetes
The National Institute for Health and Care Excellence (NICE) has revised its guidance to recommend modified-release metformin and SGLT2 inhibitors as the first-line treatment for most individuals with type 2 diabetes. This change is seen as a significant shift in practice, emphasizing a holistic approach to diabetes management that includes cardiovascular and renal health. The updated guidelines reflect the increasing prevalence of type 2 diabetes and the need for effective treatment strategies.
- ▪NICE now recommends modified-release metformin and SGLT2 inhibitors as first-line treatments for type 2 diabetes.
- ▪The update aims to improve patient adherence and reduce gastrointestinal side effects associated with standard metformin.
- ▪The guidance emphasizes a holistic approach to diabetes management, focusing on cardiovascular and renal protection.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/mr-metformin-and-sglt2i-now-first-line-type-2-diabetes-2026a1000h4s?src=rss |
| Publication time | Tue, 26 May 2026 05:27:40 EDT |
| Retrieval time | 2026-05-26T09:37:47.770Z |
| Last seen | 2026-05-26T09:37:47.770Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | oPEM6pUydmgA |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
BIRMINGHAM, UK — Modified-release (MR) metformin and a sodium-glucose cotransporter-2 inhibitor (SGLT2i) should be the first line of treatment for most people with type 2 diabetes according to revised guidance from the National Institute for Health and Care Excellence (NICE), it was reported at the Primary Care Show. This was a “game-changer” for practice, said Roy Hamilton, a GP senior partner with a specialist interest in diabetes and cardiovascular-renal-metabolic (CVRM) medicine who is based in Worcester. Metformin has been the standard of care for years, often in combination with a sulphonylurea, so it was, he said, “practice changing” to not only recommend the MR formulation over standard release but to then add in an SGLT2i.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
